ARS Pharma to submit CRL response in early Q2 2024; Q4 net loss $7.2M, cash $228.4M

ARS Pharmaceuticals, Inc.

CRL response for neffy (epinephrine nasal spray) to be submitted early Q2 2024; FDA action and potential launch expected H2 2024.
Phase 2 urticaria trial met primary endpoints with rapid symptom control; outpatient study planned later in 2024.
Cash, equivalents and short-term investments $228.4M as of Dec 31, 2023; runway at least three years.
Net loss $7.2M in Q4, $54.4M full year 2023; R&D costs $3.4M in Q4, G&A $6.8M.
EMA MAA decision for neffy expected mid-2024; new U.S. patent issued covering intranasal epinephrine methods.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.